Johnson & Johnson (NYSE:JNJ) Downgraded to “Hold” Rating by Wall Street Zen

Johnson & Johnson (NYSE:JNJ) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

JNJ has been the subject of a number of other reports. Leerink Partners lifted their target price on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Daiwa Securities Group upped their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Guggenheim raised their target price on shares of Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a report on Friday, January 23rd. Finally, Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson Trading Down 0.5%

NYSE JNJ opened at $243.37 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.80 and a current ratio of 1.03. The firm has a market cap of $586.36 billion, a price-to-earnings ratio of 22.02, a PEG ratio of 2.37 and a beta of 0.35. The firm has a 50 day simple moving average of $217.25 and a 200-day simple moving average of $196.39. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion for the quarter. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $6,924,523,000. Capital World Investors purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $2,005,942,000. Laurel Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 15,040.6% in the second quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after acquiring an additional 7,371,687 shares during the period. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock worth $49,740,362,000 after acquiring an additional 3,731,074 shares during the last quarter. Finally, Capital International Investors increased its holdings in shares of Johnson & Johnson by 93.3% in the 4th quarter. Capital International Investors now owns 7,471,031 shares of the company’s stock valued at $1,546,130,000 after acquiring an additional 3,605,981 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.